Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214987 · ClinicalTrials.gov registry record · Phase 2
PDT For Induction Therapy For Head And Neck Cancer
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT07214987: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT07214987 is a Phase 2 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214987, a Phase 2 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Toripalimab-tpzi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07214987
The ClinicalTrials.gov registry entry for NCT07214987 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT07214987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07214987 about?
NCT07214987 is a clinical study titled "PDT For Induction Therapy For Head And Neck Cancer". This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).
What is the current status of trial NCT07214987?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2026-03-09. Estimated completion is 2029-09-01.
What interventions are being tested in trial NCT07214987?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Toripalimab-tpzi (DRUG).
Who is sponsoring clinical trial NCT07214987?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.